Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab

NCT03919539 · clinicaltrials.gov ↗

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Drug Resistance to Famitinib and Camrelizumab
Biomarkers for Efficacy and Toxicity

Interventions

DIAGNOSTIC_TEST: 5hmc testing

Sponsor

Peking University People's Hospital

Collaborators

[object Object]
[object Object]